Masa Lasica, Mary A. Anderson, Alex Boussioutas, Gareth P. Gregory, Nada Hamad, Kate Manos, Penny McKelvie, Michael Ng, Belinda Campbell, Emma Palfreyman, Ross Salvaris, Robert Weinkove, Joel Wight, Stephen Opat, Constantine Tam
{"title":"边缘区淋巴瘤:澳大利亚淋巴瘤联盟的共识实践声明。","authors":"Masa Lasica, Mary A. Anderson, Alex Boussioutas, Gareth P. Gregory, Nada Hamad, Kate Manos, Penny McKelvie, Michael Ng, Belinda Campbell, Emma Palfreyman, Ross Salvaris, Robert Weinkove, Joel Wight, Stephen Opat, Constantine Tam","doi":"10.1111/imj.16390","DOIUrl":null,"url":null,"abstract":"<p>Marginal zone lymphomas (MZLs) are a rare, indolent group of non-Hodgkin lymphomas with different diagnostic, genetic and clinical features and therapeutic implications. The most common is extranodal MZL of mucosa-associated lymphoid tissue, followed by splenic MZL and nodal MZL. Patients with MZL generally have good outcomes with long survival rates but frequently have a relapsing/remitting course requiring several lines of therapy. The heterogeneous presentation and relapsing course present the clinician with several diagnostic and therapeutic challenges. This position statement presents evidence-based recommendations in the setting of Australia and New Zealand.</p>","PeriodicalId":13625,"journal":{"name":"Internal Medicine Journal","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance\",\"authors\":\"Masa Lasica, Mary A. Anderson, Alex Boussioutas, Gareth P. Gregory, Nada Hamad, Kate Manos, Penny McKelvie, Michael Ng, Belinda Campbell, Emma Palfreyman, Ross Salvaris, Robert Weinkove, Joel Wight, Stephen Opat, Constantine Tam\",\"doi\":\"10.1111/imj.16390\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Marginal zone lymphomas (MZLs) are a rare, indolent group of non-Hodgkin lymphomas with different diagnostic, genetic and clinical features and therapeutic implications. The most common is extranodal MZL of mucosa-associated lymphoid tissue, followed by splenic MZL and nodal MZL. Patients with MZL generally have good outcomes with long survival rates but frequently have a relapsing/remitting course requiring several lines of therapy. The heterogeneous presentation and relapsing course present the clinician with several diagnostic and therapeutic challenges. This position statement presents evidence-based recommendations in the setting of Australia and New Zealand.</p>\",\"PeriodicalId\":13625,\"journal\":{\"name\":\"Internal Medicine Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-06-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Internal Medicine Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/imj.16390\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine Journal","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/imj.16390","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance
Marginal zone lymphomas (MZLs) are a rare, indolent group of non-Hodgkin lymphomas with different diagnostic, genetic and clinical features and therapeutic implications. The most common is extranodal MZL of mucosa-associated lymphoid tissue, followed by splenic MZL and nodal MZL. Patients with MZL generally have good outcomes with long survival rates but frequently have a relapsing/remitting course requiring several lines of therapy. The heterogeneous presentation and relapsing course present the clinician with several diagnostic and therapeutic challenges. This position statement presents evidence-based recommendations in the setting of Australia and New Zealand.
期刊介绍:
The Internal Medicine Journal is the official journal of the Adult Medicine Division of The Royal Australasian College of Physicians (RACP). Its purpose is to publish high-quality internationally competitive peer-reviewed original medical research, both laboratory and clinical, relating to the study and research of human disease. Papers will be considered from all areas of medical practice and science. The Journal also has a major role in continuing medical education and publishes review articles relevant to physician education.